欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > Proteases/Proteasome > Odanacatib (MK-0822)

浏览历史

S80828

Odanacatib (MK-0822)

源叶(MedMol) 99%
  • 英文名:
  • Odanacatib (MK-0822)
  • 别名:
  • (2S)-N-(1-氰基环丙基)-4-氟-4-甲基-2-[[(1S)-2,2,2-三氟-1-[4'-(甲基磺酰基)[1,1'-联苯]-4-基]乙基]氨基]戊酰胺
  • CAS号:
  • 603139-19-1
  • 分子式:
  • C25H27F4N3O3S
  • 分子量:
  • 525.57
  • 核磁/质谱:
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S80828-10mg 99% ¥376.00元 7 - - - EA 加入购物车
源叶(MedMol) S80828-50mg 99% ¥1120.00元 5 - - - EA 加入购物车
源叶(MedMol) S80828-100mg 99% ¥1800.00元 4 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述: Odanacatib (MK-0822) is a potent and selective inhibitor of cathepsin K, with an IC50 of 0.2 nM for human cathepsin K.
  • 靶点: IC50: 0.2 nM (Human Cathepsin K), 1 nM (Rabbit Cathepsin K);CysteineProtease
  • 体内研究:
    Odanacatib (30 mg/kg, orally, once daily) persistently suppresses bone resorption markers and serum bone formation markers versus vehicle-treated OVX monkeys. Odanacatib displays compartment-specific effects on trabecular versus cortical bone formation, with treatment resulting in marked increases in periosteal bone formation and cortical thickness in ovariectomized monkeys whereas trabecular bone formation is reduced. The bone volume/total volume (BV/TV) and bone mineral density (BMD) of the OVX + ODN-h group is significantly higher than that of the OVX + Veh group (p < 0.05). The expressions of Runx2, Collagen-1, BSP, Osterix, OPN and SPP1 are significantly lower in the OVX + ODN-h group than in the OVX + Veh group (p < 0.01). Compared with the OVX + Veh group, the expressions of Collagen-I, BSP, Osterix, OPN and ALP reduce in the OVX + ODN-l group, but are upregulated in the OVX + ODN-h group
  • 参考文献:
    1. Jacques Yves Gauthier, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. 2. Leung P, et al. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone. 2011 Oct;49(4):623-635. 3. Ng KW. Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging. 2012;7:235-47. 4. Yi C, et al. Inhibition of cathepsin K promotes osseointegration of titanium implants in ovariectomised rats. Sci Rep. 2017 Mar 17;7:44682.
  • 溶解性: DMSO  :  ≥  25  mg/mL  (47.57  mM)
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 1.903 ml 9.513 ml 19.027 ml
    5 mM 0.381 ml 1.903 ml 3.805 ml
    10 mM 0.19 ml 0.951 ml 1.903 ml
    50 mM 0.038 ml 0.19 ml 0.381 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。